120410-24-4 Usage
Uses
Used in Pharmaceutical Industry:
Biapenem is used as a total synthesis gatifloxacin antibacterial drug for its broad-spectrum antibacterial activity against various bacteria, including gram-negative and gram-positive aerobic and anaerobic bacteria.
Used in Medical Treatment:
Biapenem is used as a carbapenem antibiotic for the treatment of patients with intra-abdominal, lower respiratory tract, and complicated urinary tract infections. It has shown good clinical and microbiological efficacy in these cases.
Used in Antibacterial Applications:
Biapenem is used as an antibacterial agent with activity against anaerobes, providing a wide range of antibacterial action.
Used in Infection Treatment:
Biapenem is used as a carbapenem antibacterial for treating bacterial infections, particularly those caused by gram-negative bacteria such as Pseudomonas aeruginosa.
Chemical Properties:
Biapenem is an off-white solid with a salt form that is soluble in water but insoluble in common organic solvents.
New carbapenem antibiotic (carbapenem family members)
Biapenem, together with several drugs developed in different companies in the United State, Japan, and China, all belong to the rapid-developing carbapenem family members. It is white to yellowish white crystalline powder, and is a kind of carbapenem-class antibiotics for injection developed by both the Lederle Company in Japan and the Cyanamid Company in the united state in 1989. It has a broad antibacterial spectrum and has an excellent bactericidal effect on Gram-negative, Gram-positive, aerobic and anaerobic bacteria. The C1 position of its structure contains a 1β-methyl group which can enable drugs to be stable to the effects of the dehydropeptidase I (DHP-I) in the human kidney without the necessity to be combined with DHP-I inhibitor for therapy, and thus reducing its renal toxicity, and is also stable to β-lactamase stability; it also has excellent pharmacokinetic properties and low toxicity; It has excellent therapeutic effect on treating various diseases such as concurrent intra-abdominal infections, plastic surgery infections, gynecological infections, ENT infections, lower respiratory tract infections (including bacterial pneumonia), and also concurrent urinary tract infections with a good tolerance and a lower incidence of adverse reactions.
A notable feature of this product is the existence of the 1β-methyl carbapenem (containing bicyclic triazole) located at the S at 2-position. Structure-function relationship studies have showed that the presence of quaternary ammonium cation located in the side chain is the key that affects the outer membrane permeability, making the inhibitory effect of the product on Pseudomonas aeruginosa and anaerobic bacteria be 2 to 4 times as potent as that of imipenem, and the inhibitory effect on the drug-resistant Pseudomonas aeruginosa be 4 to 8 times as potent as that of meropenem, and moreover, making it more effective in treating Acinetobacter spp, anaerobic bacteria than ceftazidime. Thus, it is promising that it is expected to become a novel first-line drug for treating severe infection. The general dose for intravenously infusion of Biapenem is about 300mg with time being 30~60min at 2 times per day.
Antibacterial activity
Studies have shown that biapenem has broad-spectrum and potent antibacterial activity against G+ bacteria, G-as well as anaerobic bacteria, etc. MIC90 range of this product against 456 clinical isolates of G + bacteria was 0.006~3.13μg/ml; for 1145 G-bacteria, the MIC90 range is 0.1~3.13μg/ml with its antibacterial activity being 2 times as strong as imipenem; for most anaerobes, the MIC90 range is 0.05~1.56μg/ml. Biapenem has broad-spectrum antimicrobial activity. The antimicrobial activity of it is similar as that of imipenem and meropenem, and stronger than that latamoxef and ceftazidime. The MIC value and MBC values are ??similar with each other for this drug. Upon MIC concentration, it can cause morphological changes of Pseudomonas aeruginosa and Escherichia coli; upon a concentration higher than MIC, the bacteria exhibits lytic phenomenon. Staphylococcus aureus, GPB, Streptococcus pyogenes and Streptococcus pneumoniae are highly sensitive to the drug; but methicillin-resistant Staphylococcus aureus and GPB are also resistant to this drug.
In addition, this product also has excellent antibacterial activity against Bacteriodes fragilis also with MIC90 being 1.56μg /ml. The research of Ichiro Murakami has shown that this antibacterial activity against clinical isolates of G + bacteria and Enterobacteriaceae of this drug is similar as or slightly weaker than that of imipenem, but with a stronger anti-bacterial activity against Enterobacteriaceae family than imipenem; for non G-fermentation bacteria, especially Pseudomonas aeruginosa and GM-resistant Pseudomonas aeruginosa, this antibacterial activity of this drug is two times as strong as imipenem.
Biapenem has a high affinity to the protein PBP2 and PBP4 of Pseudomonas aeruginosa, exhibiting its excellent antibacterial activity and low endotoxin release property during the bactericidal process. In 2001, the study of Japanese Scholars (Hiraishi.T) had shown that the transient bactericidal action of biapenem against Pseudomonas aeruginosa PAO1 is superior to that of meropenem. In 2005, during the comparison of transient bactericidal effects against Pseudomonas aeruginosa for biapenem, imipenem, and meropenem, Japanese scholars (Shimauchi.C) found that biapenem has a best bactericidal activity within the same treatment time.
The above information is edited by the lookchem of Dai Xiongfeng.
Indications
Sensitive strains of the drugs include: Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus (except enterococci faecium), Moraxella, Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus, Haemophilus influenzae, Pseudomonas aeruginosa, Actinomyces, Peptostreptococcus, Bacteroides, Prevotella, Fusobacterium spp.
This product is suitable for treating sensitive bacteria induced treatment sepsis, pneumonia, lung abscess, secondary infection caused by chronic respiratory disease, intractable cystitis, pyelonephritis, peritonitis, complicated cystitis, uterus annex inflammation, and gynecological annex inflammation go far.
Intellectual property status
This product was developed by Lederle Company (Japan) and Cyanamid Company (The United States) in 1989, as a novel kind of 1β-methyl carbapenem antibiotics which entered into market in Japan in March 2002. After searching, the domestic development of this product doesn’t constitute infringement to the patents in other countries; there are also no administrative protection restrictions on it.
Originator
Wyeth (US)
Antimicrobial activity
A semisynthetic carbapenem with a 2-substituted triazolium
moiety. It has broad-spectrum activity against most aerobic
and anaerobic Gram-positive and Gram-negative organisms.
It is equivalent to, or slightly more active than, imipenem
against Gram-negative aerobic bacteria and slightly less active
than imipenem against Gram-positive organisms. It is stable
to hydrolysis by dehydropeptidase. It is not hydrolyzed by
most serine β-lactamases, but like all carbapenems and penems
is readily hydrolyzed by carbapenemases. It penetrates
into bronchial epithelial lining fluid with peak concentrations
of 2.4–4.4 mg/L. The plasma half-life is 1.5–1.9 h. The potential
for neurotoxicity is less than that of imipenem.
Biochem/physiol Actions
Biapenem is a broad spectrum, carbapenem-based antibiotic with activity against both Gram-positive and Gram-negative bacterial strains.
Clinical Use
Biapenem is a newer second-generation carbapenem withchemical and microbiological properties similar to those ofmeropenem. Thus, it has broad-spectrum antibacterial activitythat includes most aerobic Gram-negative and Grampositivebacteria and anaerobes. Biapenem is stable toDHP-I67 and resistant to most β-lactamases. It is claimedto be less susceptible to metallo-β-lactamases than eitherimipenem or meropenem. It is not active orally.
Check Digit Verification of cas no
The CAS Registry Mumber 120410-24-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,0,4,1 and 0 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 120410-24:
(8*1)+(7*2)+(6*0)+(5*4)+(4*1)+(3*0)+(2*2)+(1*4)=54
54 % 10 = 4
So 120410-24-4 is a valid CAS Registry Number.
InChI:InChI=1/C18H24N4O6/c1-8-12(20-4-3-5-23)15(25)11-9(7-28-17(19)26)18(27-2)16-10(21-16)6-22(18)13(11)14(8)24/h9-10,16,20-21,23H,3-7H2,1-2H3,(H2,19,26)
120410-24-4Relevant articles and documents
Preparation method of biapenem bulk drug
-
Paragraph 0085-0087, (2020/11/26)
The invention provides a biapenem bulk drug preparation method, which comprises: 1) dissolving a biapenem crude product in water at a certain dissolving temperature T1 to prepare a biapenem crude product aqueous solution; (2) controlling the temperature of the biapenem crude product aqueous solution obtained in the step (1) to be T1 or T2, adding activated carbon with stirring for decolorization,filtering the liquid, and cooling the filtrate to T3 for later use; 3) dropwise adding the filtrate obtained in the step 2) into a mixed solvent of acetone and ethanol, which is cooled to T4 in advance, and crystallizing the filtrate; 4) growing crystal; and 5) separating, washing and drying the crystals separated out in the step 4) to obtain the biapenem bulk drug.
AN IMPROVED PROCESS FOR THE PREPARATION OF CARBAPENEM ANTIBIOTIC
-
Page/Page column 8, (2013/09/26)
The present invention relates to an improved process for the preparation of Biapenem of Formula (I) having reconstitution time less than 25 seconds. (Formula (I))
New straightforward synthesis and characterization of a unique 1β- methylcarbapenem antibiotic biapenem bearing a σ-symmetric bicyclotriazoliumthio group as the pendant moiety
Kumagai, Toshio,Tamai, Satoshi,Abe, Takao,Matsunaga, Hiroshi,Hayashi, Kazuhiko,Kishi, Ikuo,Shiro, Motoo,Nagao, Yoshimitsu
, p. 8145 - 8149 (2007/10/03)
Biapenem 1, (1R,5S,6S,)-2-[(6,7-dihydro-5H-pyrazolo[1,2- α][1,2,4]triazolium-6-yl)thio]-6-yl)thio]-6-[(R)-1-hydroxyethyl]-1- methylcarbapen-2-em-3-carboxylate, is a new non-natural 1β-methylcarbapenem antibiotic which exhibits a wide range of antibacterial activity, remarkable chemical stability, and extensive stability against human renal dehydropeptidase-I. Mercaptobicyclotriazolium chloride 2 useful for the pendant moiety of 1 was successfully synthesized starting from hydrazine hydrate 3 along an economically available synthetic route. The thiol 2 was efficiently exploited for an expeditious synthesis of biapenem 1. Characterization (crystal structure, nonbonded S- - -O interaction, conformational analysis, and CH- - -O hydrogen bonds) of 1 was investigated by its X-ray crystallographic, 1H NMR, and deuteration experiment analyses.
Heteroaryliumthio substituted carbapenem derivatives: Synthesis and in vitro activity of 1β-methyl-2-(dihydropyrrolotriazoliumthio)carbapenems
Wildonger,Ratcliffe
, p. 1866 - 1882 (2007/10/02)
The syntheses of five thiols, including three dihydropyrrolotriazoliumthiol salts, 1,4-dimethyl-5-mercaptomethyl-1,2,4-triazolium trifluoromethanesulfonate, and 6-mercapto-6,7-dihydro-5h-pyrazolo[1,2-a][1,2,4]triazolium chloride; and the addition of these thiols to 4-nitrobenzyl (IR,5R,6S)-2-(diphenylphosphono)oxy-6-[1(R)-hydroxyethyl]-1-methylcarbapen-2-cm -3-carboxylate and the subsequent hydrogenolysis of the addition products is described. The latter thiol provides a new route towards the preparation of L-627 (LJC 10,627). The compounds were evaluated in vitro against a panel of Gram-positive and Gram-negative bacteria and their antibacterial activities compared with imipenem. The compounds were measured for their hydrolytic stability to dehydropeptidase I (DHP-I) relative to imipenem. The five compounds generally had poorer Gram-positive and Pseudomonas activity than imipenem, although their Gram negative activity was variably improved. The monocyclic triazolium analog was nearly comparable in overall activity to the four bicyclic heterarylium analogs evaluated, including L-627 (LJC 10,627), All compounds were more stable to DHP-I than imipenem, although minor differences existed among them.
β-Lactams. 3. Asymmetric Total Syntheis of New Non-Natural 1β-Methylcarbapenems Exhibiting Strong Antimicrobial Activities and Stability against Human Renal Dehydropeptidase-I
Nagao, Yoshimitsu,Nagase, Yunosuke,Kumagai, Toshio,Matsunaga, Hiroshi,Abe, Takao,et al.
, p. 4243 - 4249 (2007/10/02)
Asymmetric synthesis of 11, the precursor to chiral (3R,4R)-3-ethyl>-4-acetoxyazetidin-2-one (3) was achieved by utilizing a highly diastereoselective aldol-type reaction of acetaldehyde and the chiral tin(II) enolate of 5.Similar diastereoselective alkylations of chiral and achiral tin(II) enolates 13a-d with chiral 3 were also performed to obtain the desired alkylated azetidin-2-ones (17a-d).Compounds 17a,b were successfully converted to new, non-natural 1β-methylcarbapenems 1a and 1b, which exhibited strong and wide-ranging antimicrobial activities and excellent stability against human renal dehydropeptidase-I.
